Department of Internal Medicine, Hamidiye Sisli Etfal Education and Research Hospital, Istanbul, Turkey.
Department of Infection, Hamidiye Sisli Etfal Education and Research Hospital, Huzur Mah. Cumhuriyet&Demokrasi Cad. No 1/3. Sariyer, Istanbul, Turkey.
Virol J. 2022 Jan 6;19(1):9. doi: 10.1186/s12985-021-01736-4.
Multisystem inflammatory syndrome (MIS), which develops after a past covid-19 infection. MIS can be described in different tissue inflammation, including the heart, lung, kidney, brain, skin, eye, and or gastrointestinal organs at the presence of COVID-19. Initially, MIS was described in Europe in children infected with SARS-CoV-2, then it was recently seen in the USA in 2020. MIS is a rare but serious disease condition associated with COVID-19 that can affect children (MIS-C) and adults (MIS-A).
A 44-year-old male who showed MIS-A in 59-day after his first covid-19 contact history. The patient presented to our emergency department with complaints of high fever, nausea, weakness, redness of the eyes, headache, and joint pain. On the second day of his hospitalization, a maculopapular skin lesion was seen in most of the skin. His fever could not be controlled even given paracetamol and broad effective antibiotics. His clinical, radiological, and laboratory findings showed that he had MIS-A. The patient was given intravenous pulse methylprednisolone and intravenous immunoglobulin (IVIG). These treatments, then, resulted in improvement of his clinical conditions, including fever and skin lesions, on the second day of the treatment. The patient was discharged in 14 days after the treatment.
This report indicated that diagnosis and treatment of MIS-A could result in reducing patient morbidity and mortality.
多系统炎症综合征（MIS）是在过去的新冠病毒感染后发展而来的。MIS 可以在不同的组织炎症中描述，包括心脏、肺、肾、脑、皮肤、眼睛和/或胃肠道器官，同时存在 COVID-19。最初，MIS 在欧洲被描述为感染 SARS-CoV-2 的儿童，然后最近在美国 2020 年也被发现。MIS 是一种罕见但严重的疾病，与 COVID-19 有关，可影响儿童（MIS-C）和成人（MIS-A）。
一名 44 岁男性，在首次接触新冠病毒 59 天后出现 MIS-A。该患者因高热、恶心、乏力、眼红、头痛和关节痛就诊于我院急诊科。入院第二天，大多数皮肤出现斑丘疹样皮损。即使给予扑热息痛和广谱有效抗生素，他的发热仍无法控制。他的临床、放射学和实验室检查结果显示他患有 MIS-A。患者给予静脉注射脉冲甲基强的松龙和静脉注射免疫球蛋白（IVIG）。这些治疗措施随后导致他的临床状况（包括发热和皮肤损伤）在治疗第二天得到改善。治疗 14 天后患者出院。
本报告表明，MIS-A 的诊断和治疗可以降低患者的发病率和死亡率。
